{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["MacInnis RJ"],"funding":["US government","NCI NIH HHS"],"pagination":["pkae121"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11700558"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing associations may differ by familial risk of breast cancer and CRC. We harmonized data from 3 cohorts and generated separate breast cancer and CRC familial risk scores based on cancer family history. We defined moderate or strong family history as a risk score of 0.4 or higher, where 0.4 was equivalent to a 50-year-old woman with 1 parent diagnosed with either breast cancer or CRC at 55 years of age. Of 24 486 women assessed, 1243 and 405 were diagnosed with incident breast cancer and CRC, respectively. For breast cancer, menopausal HRT ever use versus never use hazard ratios were 1.27 (95% "],"journal":["JNCI cancer spectrum"],"pubmed_title":["Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk."],"pmcid":["PMC11700558"],"funding_grant_id":["U01 CA167551"],"pubmed_authors":["Milne RL","Southey MC","Andrulis IL","Macrae FA","Pai RK","Samadder NJ","Le Marchand L","Phipps AI","Phillips KA","Schmit SL","Hopper JL","Terry MB","Gallinger S","Colonna SV","Jenkins MA","kConFab Investigators","Giles GG","Daly MB","Newcomb PA","Buchanan DD","MacInnis RJ","John EM"],"additional_accession":[]},"is_claimable":false,"name":"Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk.","description":"Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing associations may differ by familial risk of breast cancer and CRC. We harmonized data from 3 cohorts and generated separate breast cancer and CRC familial risk scores based on cancer family history. We defined moderate or strong family history as a risk score of 0.4 or higher, where 0.4 was equivalent to a 50-year-old woman with 1 parent diagnosed with either breast cancer or CRC at 55 years of age. Of 24 486 women assessed, 1243 and 405 were diagnosed with incident breast cancer and CRC, respectively. For breast cancer, menopausal HRT ever use versus never use hazard ratios were 1.27 (95% ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-18T13:01:49.061Z","creation":"2025-04-06T22:28:46.865Z"},"accession":"S-EPMC11700558","cross_references":{"pubmed":["39673461"],"doi":["10.1093/jncics/pkae121"]}}